Exidavnemab phase 2a study expanded to include MSA patients
Go back to Exidavnemab phase 2a study expanded to include MSA patients| BARNES GROUP, Inc. (NYSE: B) | Delayed: 35.69 -1 (2.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.69 | 52 Week High | $44.27 | |||
| Open | $36.57 | 52 Week Low | $30.07 | |||
| Day High | $36.64 | P/E | 27.24 | |||
| Day Low | $35.48 | EPS | $1.31 | |||
| Volume | 2,609,025 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 20.96 -0.96 (4.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.92 | 52 Week High | $8.73 | |||
| Open | $21.96 | 52 Week Low | $2.86 | |||
| Day High | $22.48 | P/E | N/A | |||
| Day Low | $20.39 | EPS | $-3.82 | |||
| Volume | 195,626 | |||||
